Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$3.66-1.2%$2.74$1.94▼$12.32$5.46M0.16123,666 shs8,809 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma-1.19%+13.54%+48.98%-24.15%-32.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVOKEvoke Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVOKEvoke Pharma$11.59M0.47N/AN/A($9.26) per share-0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVOKEvoke Pharma-$7.79M-$2.87N/A∞N/A-71.32%-308.49%-53.66%8/11/2025 (Estimated)Latest 888, RNK, JPJ, and EVOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million3/13/2025Q4 2024EVOKEvoke Pharma-$0.25-$0.49-$0.24-$0.49$3.08 million$3.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVOKEvoke PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVOKEvoke PharmaN/A1.441.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVOKEvoke PharmaN/AInsider OwnershipCompanyInsider OwnershipEVOKEvoke Pharma2.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVOKEvoke Pharma41.49 million1.40 millionNot Optionable888, RNK, JPJ, and EVOK HeadlinesRecent News About These CompaniesEvoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.comMay 17, 2025 | americanbankingnews.comEvoke Pharma Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comInizio Evoke appoints Tristen George and Kevin Kaniuga as executive creative directorsMay 10, 2025 | pmlive.comEvoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025April 30, 2025 | nasdaq.comEvoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025April 28, 2025 | globenewswire.comevoke makes a steady exit from the Q1 starting gateApril 25, 2025 | proactiveinvestors.co.ukWilliam Hill owner Evoke falls at the first-quarter updateMarch 26, 2025 | proactiveinvestors.co.ukEvoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 16, 2025 | uk.finance.yahoo.comEarnings call transcript: Evoke Pharma Q4 2024 reports strong sales growthMarch 15, 2025 | uk.investing.comQ4 2024 Evoke Pharma Inc Earnings CallMarch 14, 2025 | finance.yahoo.comEvoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comEvoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...March 13, 2025 | gurufocus.comEvoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 13, 2025 | globenewswire.comEvoke Pharma, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025March 6, 2025 | quiverquant.comEvoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025March 6, 2025 | globenewswire.comEvoke Pharma, Inc. Appoints Greg Pyszczymuka to Board of Directors, Strengthening Commercial StrategyFebruary 24, 2025 | quiverquant.comEvoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of DirectorsFebruary 24, 2025 | globenewswire.comWilliam Hill owner Evoke expects earnings to beat market forecastsJanuary 17, 2025 | proactiveinvestors.co.ukWilliam Hill owner Evoke expects earnings to beat market forecastsJanuary 17, 2025 | proactiveinvestors.co.ukHere’s Why Evoke Pharma, Inc. (NASDAQ:EVOK) Is Among the Best Diabetes Stocks to Buy Under $10January 6, 2025 | insidermonkey.comMedia Sentiment Over Time888, RNK, JPJ, and EVOK Company DescriptionsEvoke Pharma NASDAQ:EVOK$3.66 -0.04 (-1.19%) Closing price 05/23/2025 03:02 PM EasternExtended Trading$3.69 +0.03 (+0.90%) As of 05/23/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
